AstraZeneca's Calquence steps up to challenge Imbruvica with big CLL green light

Johnson & Johnson and AbbVie’s Imbruvica has enjoyed a nice run in previously untreated chronic lymphocytic leukemia over the last few years. But major competition is here in the form of AstraZeneca’s Calquence.